Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis

BACKGROUND: Real-world data regarding outcomes of idiopathic pulmonary fibrosis (IPF) are scarce, outside of registries. In France, pirfenidone and nintedanib are only reimbursed for documented IPF, with similar reimbursement criteria with respect to disease characteristics, prescription through a d...

Descripción completa

Detalles Bibliográficos
Autores principales: Belhassen, Manon, Dalon, Faustine, Nolin, Maëva, Van Ganse, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094468/
https://www.ncbi.nlm.nih.gov/pubmed/33947414
http://dx.doi.org/10.1186/s12931-021-01714-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094468/
https://www.ncbi.nlm.nih.gov/pubmed/33947414
http://dx.doi.org/10.1186/s12931-021-01714-y

Ejemplares similares